Axsome Therapeutics is trading at $225.99 (5.2% down) in pre-market as the stock pulls back from last week's rally in the absence of new catalysts.
- No fresh company-specific headlines, earnings reports, or FDA decisions have been identified as drivers for the move.
- The decline likely reflects profit-taking or normal volatility, given that broader U.S. indices are only slightly weaker.